50 results
8-K
EX-99.2
ADAP
Adaptimmune Therapeutics Plc
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926; or SVB … Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6218
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
2 Jun 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
4:49pm
Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297 … -2926; orSVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6218
NT 10-K
ADAP
Adaptimmune Therapeutics Plc
1 Mar 22
Notice of late annual filing
4:30pm
department affecting the general review process and has not permitted the Company’s independent registered public accounting firm to complete their audit
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
7 Feb 20
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
4:20pm
, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests
F-6EF
EX-99
ADAP
Adaptimmune Therapeutics Plc
30 Aug 19
Automatic registration for ADRs (foreign)
1:06pm
August 30, 2019
Citibank, N.A. – ADR Department
388 Greenwich Street
New York, New York 10013
Ladies and Gentlemen:
We refer to the Registration
8-K
EX-99.1
ict3j l2f1smccb
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
8-K
EX-14.1
fu0x8h9nnmhsikmfn84d
24 Jul 17
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
12:00am
8-K
EX-99.2
s7z8y6
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
8-K
EX-99.1
9pbcz8la5 o3
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
8-K
fqfpchv5r4x3wt7ipvu
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
8-K
EX-99.1
lhj04kvsugrvfh y6
20 Nov 20
Regulation FD Disclosure
7:36am
8-K
EX-99.1
6v0z6gq2ulw
13 Sep 21
Other Events
7:08am
8-K
7jipy4x9
22 May 23
Other Events
6:59am
8-K
EX-99.1
w3xz3o zg11u
4 Nov 21
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:40am
425
akepq u2np
22 May 23
Business combination disclosure
7:01am
8-K
EX-99.1
6mi98d 9ayq4
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
S-3ASR
EX-1.2
3c8szimuq9z3qr8cc
10 Aug 20
Automatic shelf registration
5:01pm